Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Atea Pharmaceuticals Q3 2026 Results: Net Loss of $32.2M, Loss Narrows

Atea Pharmaceuticals reported a net loss of $32.2 million for the third quarter of 2026, an improvement from the $42.0 million loss in the prior year period. Total current assets decreased significantly from $311.0 million at year-end 2025 to $200.3 million as of September 30, 2026, primarily driven by a reduction in marketable securities used to fund operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-32.1-41.9
Net income-32.2-42.0
EPS (diluted, $ a share)$-0.40$-0.53

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: AVIR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Atea Pharmaceuticals, Inc.: key numbers

Share price
$4.12Close, Nov 16
Market cap
$331M
Shares outstanding
80.3MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Atea Pharmaceuticals, Inc.

All →
4:18 PM ET 8-K
Financial Results

Atea Pharmaceuticals Financial Results

Atea Pharmaceuticals reported Q3 2026 financial results and provided a clinical update on its Phase 3 C-BEYOND trial for Hepatitis C, which met its primary and secondary endpoints. The company also secured up to $200 million in non-dilutive funding from Hercules Capital and expects topline results from its Phase 3 C-FORWARD trial in early 2027.

Term
Q3 2026

“The C-BEYOND results are strong and reinforce our conviction that the regimen of BEM/RZR will deliver a differentiated profile, including high HCV cure rates, short treatment duration, a low risk of drug-drug interactions and no food effect, which we believe are critical to drive broad adoption of BEM/RZR in clinical practice by prescribers.”

Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals

“We anticipate the upcoming topline Phase 3 results of C-FORWARD should further validate the potential of BEM/RZR, if approved, to be a new pan-genotypic treatment option for prescribers to treat people living with HCV.”

Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals
7:30 AM ET 8-K
Loan & Debt

Atea Pharmaceuticals $200M Debt Financing with Hercules Capital, Inc.

Atea Pharmaceuticals entered into a $200 million senior secured term loan facility with Hercules Capital, with an initial $65 million drawn at closing. Additional tranches are available upon achieving clinical and commercial milestones related to the bemnifosbuvir and ruzasvir (BEM/RZR) program. The facility matures in November 2031 and carries a floating interest rate starting at a minimum of 9.35%.

Value
$200M
Counterparty
Hercules Capital, Inc.
Term
through Nov 2031

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.